PROTALIX BIOTHERAPEUTICS, INC. COMMON STOCK (AM:PLX)

View All ReportsStreetInsider.com Reports on PLX

Nov 24, 2009 11:06 AM Protalix BioTherapeutics (PLX) Sees Interest On Renewed Takeover Talk

Nov 13, 2009 11:51 AM Traders Watching Protalix (PLX) On Genzyme News

Nov 13, 2009 11:22 AM Protalix BioThera (PLX) May Have a Winner with Gaucher Drug prGCD

Nov 10, 2009 12:51 PM Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)

Nov 2, 2009 08:50 AM Now Pfizer Is Rumored To Be Interested In Protalix (PLX)

View All Press ReleasesCompany Press Releases on PLX

Oct 29, 2009 07:30AM Protalix BioTherapeutics to Present at the Oppenheimer 20th Annual Healthcare Conference

Oct 15, 2009 06:00AM Protalix BioTherapeutics Announces Positive Top-line Results from its Phase III Clinical Trial of UPLYSO(TM) for the Treatment of Gaucher Disease

StreetInsider Reports on PLX by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on PLX

Nov 17, 2009 09:00 AM Lumizyme Rejected Again: Downgrading Genzyme Recommendation from Buy to Hold

Nov 16, 2009 09:37 AM Insiders Still Quite Bearish on Their Own Companies

Oct 30, 2009 05:40 AM Genzyme: Focusing on Lumizyme Approval

Oct 15, 2009 11:05 AM BioMed News Bytes: Protalix, Soligenix

Oct 6, 2009 09:39 AM Trial Setback Is Welcome News for Genzyme, But Don't Get Too Excited

View All FilingsSEC Filings on PLX

Nov 13, 2009 04:31PM Form 4 Protalix BioTherapeutics For: Nov 12 Filed by: Hurvitz Eli

Nov 9, 2009 04:31PM Form 10-Q Protalix BioTherapeutics For: Sep 30

Oct 21, 2009 08:02PM Form 4 Protalix BioTherapeutics For: Oct 19 Filed by: Aviezer David

Oct 19, 2009 08:49PM Form 4 Protalix BioTherapeutics For: Oct 15 Filed by: Almon Einat Brill

Oct 19, 2009 08:45PM Form 4 Protalix BioTherapeutics For: Oct 15 Filed by: Shaaltiel Yoseph

Comments on recent PLX articles

Ken
on Nov 19, 2009
at 10:11 AM PLX Why is this stock down over the last week?
Article: Protalix BioThera (PLX) May Have a Winner with Gaucher Drug prGCD

Land
on Nov 10, 2009
at 05:36 PM Takeover speculaton When one reads the statement that accompanied the Q3 financials, it is clear that protalix is much more than a one trick pony. Not only is a drug now ready for finai approval for Gauchers disease with potential annual sales of $120 to 200,000,000 but the company is making excellent progress on another enzyme treatment, a biological weapons defense medication, a rhematoid arthritis treatment, and at least one other drug for an undisclosed ailment. All are bio-idential to existing drugs (except the bio-defense one) with existing markets so the clinical trials a little less complicated. They might partner withanother company to license the basic method of production they should continue to develop and sel leverything they can produce. If the bio-defense medication is effective, it willl be ordered by every army in the world. If the other drugs are effective, their sales could easily be (like Gensyme) in the billions. If antoher company wants everything including the entire pipeline, the price has to be very very high.
Article: Canaccord Adams Reiterates a 'Buy' on Protalix BioTherapeutics (PLX)

Iki
on Sep 2, 2009
at 05:15 PM $10 is under esstimation !! Would like to emphsize that the holders can easily get more than $1B for FDA approved company, while $1B represent $13 of 76MM outstanding stocks. Profesionals can tell that the holder will not give up the company for much more...
Article: Hapoalim Securities Initiates Coverage on Protalix BioTherapeutics (PLX) with an Outperform; Attractive Entry Point

Comments on PLX

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?